DISLIPIDEMIYA VA OVQATLANISH OMILLARINING YURAK ISHEMIK KASALLIGI RIVOJLANISHIGA TA’SIRI

Authors

  • Jo‘rayeva Ruxshona Annaqul qizi Toshkent davlat tibbiyot Universiteti, talaba Author
  • Axmadaliyeva Nigora Odilovna Toshkent davlat tibbiyot Universiteti, t.f.d., dotsent Author

Keywords:

Dislipidemiya, yurak ishemik kasalligi, ateroskleroz, lipid metabolizmi, ovqatlanish omillari, omega-3 yog‘ kislotalari, aterogen lipoproteidlar, metabolik sindrom

Abstract

Mazkur ilmiy adabiyotlar sharhida dislipidemiya va ovqatlanish omillarining yurak ishemik kasalligi rivojlanishidagi patogenetik hamda epidemiologik ahamiyati tahlil qilindi. Zamonaviy ilmiy manbalar asosida lipid almashinuvining buzilishi, ateroskleroz, surunkali yallig‘lanish va metabolik sindrom o‘rtasidagi bog‘liqlik baholandi. Tahlillar noto‘g‘ri ovqatlanish, trans-yog‘lar va ultra-protsesslangan mahsulotlar YUIK xavfini oshirishini ko‘rsatdi. O‘rta yer dengizi dietasi, omega-3 yog‘ kislotalari va yuqori tolali ratsion esa kardioprotektiv ta’sir namoyon qilishi aniqlandi. Ratsional ovqatlanish va lipid profilini nazorat qilish YUIK profilaktikasining muhim komponenti hisoblanadi.

Downloads

Download data is not yet available.

References

1. Mach, F., et al. (2020). ESC/EAS Guidelines for dyslipidaemias. European Heart Journal, 41(1), 111–188. https://doi.org/10.1093/eurheartj/ehz455

2. Libby, P. (2021). The changing landscape of atherosclerosis. Nature, 592(7855), 524–533. https://doi.org/10.1038/s41586-021-03392-8

3. Cholesterol Treatment Trialists’ Collaboration. (2019). Efficacy of statins. The Lancet, 393(10170), 407–415. https://doi.org/10.1016/S0140-6736(18)31942-1

4. Ference, B. A., et al. (2019). LDL causes atherosclerotic disease. European Heart Journal, 38(32), 2459–2472. https://doi.org/10.1093/eurheartj/ehx144

5. Sniderman, A. D., et al. (2019). Apolipoprotein B in cardiovascular disease. JAMA Cardiology, 4(12), 1287–1295. https://doi.org/10.1001/jamacardio.2019.3780

6. GBD 2023 Risk Factors Collaborators. (2025). Global burden attributable to metabolic risks. The Lancet, 405(10474), 1123–1156. https://doi.org/10.1016/S0140-6736(25)00312-7

7. Roth, G. A., et al. (2020). Global burden of cardiovascular diseases. Journal of the American College of Cardiology, 76(25), 2982–3021. https://doi.org/10.1016/j.jacc.2020.11.010

8. Yusuf, S., et al. (2004). INTERHEART study. The Lancet, 364(9438), 937–952. https://doi.org/10.1016/S0140-6736(04)17018-9

9. Dawber, T. R., et al. (1951). Framingham study. American Journal of Public Health, 41(3), 279–286. https://doi.org/10.2105/AJPH.41.3.279

10. Dehghan, M., et al. (2017). PURE study. The Lancet, 390(10107), 2050–2062. https://doi.org/10.1016/S0140-6736(17)32252-3

11. Welsh, C., et al. (2019). Triglycerides and coronary disease. Circulation, 139(24), 2821–2830. https://doi.org/10.1161/CIRCULATIONAHA.118.037858

12. Bild, D. E., et al. (2002). MESA study. American Journal of Epidemiology, 156(9), 871–881. https://doi.org/10.1093/aje/kwf113

13. Hu, F. B., & Willett, W. C. (2002). Optimal diets for prevention. JAMA, 288(20), 2569–2578. https://doi.org/10.1001/jama.288.20.2569

14. Mozaffarian, D., et al. (2006). Trans fatty acids and cardiovascular disease. New England Journal of Medicine, 354(15), 1601–1613. https://doi.org/10.1056/NEJMra054035

15. Srour, B., et al. (2019). Ultra-processed food intake and cardiovascular disease. BMJ, 365, l1451. https://doi.org/10.1136/bmj.l1451

16. Willett, W. C., et al. (2019). Mediterranean diet. American Journal of Clinical Nutrition, 61(6), 1402S–1406S. https://doi.org/10.1093/ajcn/61.6.1402S

17. Estruch, R., et al. (2018). Mediterranean diet trial. New England Journal of Medicine, 378(25), e34. https://doi.org/10.1056/NEJMoa1800389

18. Siervo, M., et al. (2015). DASH diet meta-analysis. British Journal of Nutrition, 113(1), 1–15. https://doi.org/10.1017/S0007114514003341

19. Reynolds, A., et al. (2019). Dietary fiber and cardiovascular outcomes. The Lancet, 393(10170), 434–445. https://doi.org/10.1016/S0140-6736(18)31809-9

20. Calder, P. C. (2017). Omega-3 fatty acids and cardiovascular disease. Biochimica et Biophysica Acta, 1851(4), 469–484. https://doi.org/10.1016/j.bbalip.2014.08.010

21. Bhatt, D. L., et al. (2019). REDUCE-IT trial. New England Journal of Medicine, 380(1), 11–22. https://doi.org/10.1056/NEJMoa1812792

22. Mozaffarian, D., & Rimm, E. B. (2006). Fish intake and cardiovascular disease. JAMA, 296(15), 1885–1899. https://doi.org/10.1001/jama.296.15.1885

23. Eckel, R. H., et al. (2018). Obesity and diabetes. Circulation Research, 122(11), 1527–1532. https://doi.org/10.1161/CIRCRESAHA.118.312782

24. Després, J. P. (2016). Visceral obesity. Circulation, 126(10), 1301–1313. https://doi.org/10.1161/CIRCULATIONAHA.111.067264

25. Ford, E. S., et al. (2002). Metabolic syndrome prevalence. JAMA, 287(3), 356–359. https://doi.org/10.1001/jama.287.3.356

26. Hansson, G. K. (2005). Inflammation and atherosclerosis. New England Journal of Medicine, 352(16), 1685–1695. https://doi.org/10.1056/NEJMra043430

27. Ridker, P. M. (2016). Inflammation in atherosclerosis. European Heart Journal, 37(36), 2920–2922. https://doi.org/10.1093/eurheartj/ehw240

28. Ridker, P. M., et al. (2017). CANTOS trial. New England Journal of Medicine, 377(12), 1119–1131. https://doi.org/10.1056/NEJMoa1707914

29. Kathiresan, S. (2017). Genetics of coronary artery disease. New England Journal of Medicine, 375(24), 2349–2361. https://doi.org/10.1056/NEJMra1609501

30. Ordovas, J. M., et al. (2018). Precision nutrition. Nature Reviews Cardiology, 15(11), 631–642. https://doi.org/10.1038/s41569-018-0075-5

31. Zeevi, D., et al. (2015). Personalized nutrition. Cell, 163(5), 1079–1094. https://doi.org/10.1016/j.cell.2015.11.001

32. Baigent, C., et al. (2010). Statin meta-analysis. The Lancet, 376(9753), 1670–1681. https://doi.org/10.1016/S0140-6736(10)61350-5

33. Sabatine, M. S., et al. (2017). FOURIER trial. New England Journal of Medicine, 376(18), 1713–1722. https://doi.org/10.1056/NEJMoa1615664

34. Cannon, C. P., et al. (2015). IMPROVE-IT trial. New England Journal of Medicine, 372(25), 2387–2397. https://doi.org/10.1056/NEJMoa1410489

35. Afshin, A., et al. (2019). Dietary risks in 195 countries. The Lancet, 393(10184), 1958–1972. https://doi.org/10.1016/S0140-6736(19)30041-8

36. Virani, S. S., et al. (2021). Heart disease statistics. Circulation, 143(8), e254–e743. https://doi.org/10.1161/CIR.0000000000000950

37. World Health Organization. (2025). Cardiovascular diseases (CVDs). https://www.who.int/en/news-room/fact-sheets/detail/cardiovascular-diseases-%28cvds%29

38. Libby, P. (2021). The changing landscape of atherosclerosis. Nature, 592(7855), 524–533. https://doi.org/10.1038/s41586-021-03392-8

39. Ference, B. A., et al. (2019). Low-density lipoproteins cause atherosclerotic cardiovascular disease. European Heart Journal, 38(32), 2459–2472. https://doi.org/10.1093/eurheartj/ehx144

40. Mach, F., et al. (2020). ESC/EAS Guidelines for dyslipidaemias. European Heart Journal, 41(1), 111–188. https://doi.org/10.1093/eurheartj/ehz455

41. Hansson, G. K. (2020). Inflammation, atherosclerosis, and coronary artery disease. New England Journal of Medicine, 352(16), 1685–1695. https://doi.org/10.1056/NEJMra043430

42. Tabas, I., & Bornfeldt, K. E. (2020). Macrophage phenotype and function in different stages of atherosclerosis. Circulation Research, 118(4), 653–667. https://doi.org/10.1161/CIRCRESAHA.115.306256

43. Mozaffarian, D. (2016). Dietary and policy priorities for cardiovascular disease. Circulation, 133(2), 187–225. https://doi.org/10.1161/CIRCULATIONAHA.115.018585

Downloads

Published

2026-05-16

Issue

Vol. 5 No. 3 (2026): EIYB (Educational Yield Insights & Breakthroughs)

Section

Articles